Apoptotic Pathway Defects in Neuroblastoma
神经母细胞瘤的凋亡途径缺陷
基本信息
- 批准号:6697051
- 负责人:
- 金额:$ 33.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1995
- 资助国家:美国
- 起止时间:1995-07-15 至 2007-12-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Late stage neuroblastoma tumors, particularly those with amplified MYCN genes, have a poor prognosis, primarily due to their ability to survive treatment with multiple chemotherapeutic agents/irradiation. The continuing goal of this research program is to understand how genetic alterations, such as MYCN gene amplification and chromosome lp36 loss-of-heterozygosity (LOH), contribute to this tumor phenotype. During the last funding period we found that a critical apoptotic signaling molecule, caspase-8, is preferentially silenced by methylation in >60% of the stage 4 neuroblastoma patient tumors with simplified MYCN, whereas <4% of those stage 1-4 tumors without amplified MYCN silence expression of the CASP8 gene. A similar observation has now been made in N-Myc-induced neuroblastoma tumors from mice. We also found that reprogramed expression of caspase-8 in human NB cells that are normally caspase-8 null resensitized them to apoptosis induced by the chemotherapeutic drugs doxorubicin and cisplatin. This was observed in both cell culture and in vivo xenograft mouse models. Finally, we have reported, as have others, that caspase-8 is capable of functioning as both an initiator and executioner caspase, allowing it to amplify certain mitochondrial-mediated cell death signals. This function is somewhat unique among the caspases identified thus far, and could be one reason it is selectively silenced in certain tumors. Based upon this data we hypothesize that the silencing of CASP8 by methylation may provide a more permissive cellular environment that can tolerate the overexpression of N-Myc without undergoing cell death, and perhaps contribute to the ability of these tumor cells to survive treatment with certain chemotherapeutic drugs. To test this hypothesis we propose to develop mouse models by gene knockout or transgenic expression of an inactive, dominant negative form of caspase-8 that either totally eliminate, or down-regulate enzyme activity, and determine whether it contributes to accelerated tumor cell growth in the presence of N-Myc overexpression or the response of these tumors to chemotherapeutic drugs. These experiments will include the use of complementary approaches; namely the induction of oncogenes such as MYCN in cultured neural crest cells isolated from these mice, as well as the response of the various cells, xenografts, and in vivo tumors to therapy. Finally, we will examine these different mouse NB tumors and normal adrenal gland tissue, as well as human patient samples of various stages and matched-treated/untreated samples by microarray analysis to identify possible genes, other than CASP8, whose expression is significantly altered by N-Myc overexpression and/or drug treatment. Such studies will provide significant insight into how these tumor cells circumvent apoptosis and prolong their life.
描述(由申请人提供):晚期神经母细胞瘤,特别是MYCN基因扩增的神经母细胞瘤,预后较差,主要是由于它们在多种化疗药物/放射治疗下存活的能力。该研究计划的持续目标是了解遗传改变,如MYCN基因扩增和染色体lp36杂合性缺失(LOH),如何促成这种肿瘤表型。在最后的资助期内,我们发现一个关键的凋亡信号分子caspase-8,在约60%具有简化MYCN的4期神经母细胞瘤患者中优先被甲基化沉默,而在没有扩增MYCN的1-4期肿瘤中,只有不到4%的患者沉默CASP8基因的表达。现在在小鼠n - myc诱导的神经母细胞瘤肿瘤中也进行了类似的观察。我们还发现,在正常情况下caspase-8缺失的人NB细胞中,caspase-8的重编程表达使它们对化疗药物阿霉素和顺铂诱导的细胞凋亡重新敏感。这在细胞培养和体内异种移植小鼠模型中都观察到了。最后,我们和其他人一样报道了caspase-8能够同时作为启动者和执行者caspase,使其能够放大某些线粒体介导的细胞死亡信号。这种功能在目前已发现的半胱天冬酶中有些独特,这可能是它在某些肿瘤中选择性沉默的原因之一。基于这些数据,我们假设通过甲基化沉默CASP8可能提供一个更宽容的细胞环境,可以耐受N-Myc的过度表达而不发生细胞死亡,并且可能有助于这些肿瘤细胞在某些化疗药物治疗下存活的能力。为了验证这一假设,我们建议通过基因敲除或转基因表达无活性的caspase-8显性阴性形式来建立小鼠模型,从而完全消除或下调酶活性,并确定它是否有助于在N-Myc过度表达的情况下加速肿瘤细胞生长或这些肿瘤对化疗药物的反应。这些实验将包括使用补充方法;即在从这些小鼠分离的培养的神经嵴细胞中诱导致癌基因,如MYCN,以及各种细胞、异种移植物和体内肿瘤对治疗的反应。最后,我们将通过微阵列分析检查这些不同的小鼠NB肿瘤和正常肾上腺组织,以及不同阶段的人类患者样本和匹配治疗/未治疗的样本,以确定除CASP8外,其表达因N-Myc过表达和/或药物治疗而显着改变的可能基因。这些研究将为这些肿瘤细胞如何规避凋亡并延长其生命提供重要的见解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JILL M LAHTI其他文献
JILL M LAHTI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JILL M LAHTI', 18)}}的其他基金
Functional Analysis of CDKp110 Protein Kinase
CDKp110蛋白激酶的功能分析
- 批准号:
7988968 - 财政年份:2009
- 资助金额:
$ 33.75万 - 项目类别:
REGULATION OF CYCLIN C FUNCTION IN TUMORS & NORMAL CELLS
肿瘤中细胞周期蛋白 C 功能的调节
- 批准号:
6164228 - 财政年份:1997
- 资助金额:
$ 33.75万 - 项目类别:
REGULATION OF CYCLIN C FUNCTION IN TUMORS & NORMAL CELLS
肿瘤中细胞周期蛋白 C 功能的调节
- 批准号:
2668059 - 财政年份:1997
- 资助金额:
$ 33.75万 - 项目类别:
REGULATION OF CYCLIN C FUNCTION IN TUMORS & NORMAL CELLS
肿瘤中细胞周期蛋白 C 功能的调节
- 批准号:
6362617 - 财政年份:1997
- 资助金额:
$ 33.75万 - 项目类别:
REGULATION OF CYCLIN C FUNCTION IN TUMORS & NORMAL CELLS
肿瘤中细胞周期蛋白 C 功能的调节
- 批准号:
2010643 - 财政年份:1997
- 资助金额:
$ 33.75万 - 项目类别:
REGULATION OF CYCLIN C FUNCTION IN TUMORS & NORMAL CELLS
肿瘤中细胞周期蛋白 C 功能的调节
- 批准号:
2882465 - 财政年份:1997
- 资助金额:
$ 33.75万 - 项目类别:
相似国自然基金
复杂疾病多态性miRNA-mRNA-pathway致病模式挖掘研究
- 批准号:2020JJ4209
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
软骨细胞介导外泌体调节软骨下骨祖细胞Wnt/β-catenin pathway在骨关节炎中的作用及其机制研究
- 批准号:81972087
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
Ptch1 基因通过 Hh 信号通路(Hedgehog signaling pathway)对卵巢癌细胞增殖和凋亡的影响
- 批准号:
- 批准年份:2019
- 资助金额:3.0 万元
- 项目类别:省市级项目
Drug-ADR-Pathway复合网络构建及ADR分子机制研究
- 批准号:61372188
- 批准年份:2013
- 资助金额:80.0 万元
- 项目类别:面上项目
基于protein pathway array 技术导向的胃癌淋巴结转移预警蛋白表达特征的研究
- 批准号:81372295
- 批准年份:2013
- 资助金额:62.0 万元
- 项目类别:面上项目
miR-143/HDAC7 pathway 通过调控组蛋白乙酰化改变影响骨肉瘤转移特性的分子机制研究
- 批准号:81202122
- 批准年份:2012
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
- 批准号:30840003
- 批准年份:2008
- 资助金额:12.0 万元
- 项目类别:专项基金项目
pathway预测方法研究
- 批准号:60873146
- 批准年份:2008
- 资助金额:38.0 万元
- 项目类别:面上项目
Wnt pathway对大脑皮质桶发育调控机制的研究
- 批准号:30770696
- 批准年份:2007
- 资助金额:30.0 万元
- 项目类别:面上项目
相似海外基金
Neurodevelopmental defects of the thalamocortical pathway as a convergent feature of psychiatric disorders
丘脑皮质通路的神经发育缺陷是精神疾病的共同特征
- 批准号:
10655225 - 财政年份:2023
- 资助金额:
$ 33.75万 - 项目类别:
How BANK1 pathway defects in B cells cause human lupus
B 细胞中 BANK1 通路缺陷如何导致人类狼疮
- 批准号:
nhmrc : 1125513 - 财政年份:2017
- 资助金额:
$ 33.75万 - 项目类别:
Project Grants
How BANK1 pathway defects in B cells cause human lupus
B 细胞中 BANK1 通路缺陷如何导致人类狼疮
- 批准号:
nhmrc : GNT1125513 - 财政年份:2017
- 资助金额:
$ 33.75万 - 项目类别:
Project Grants
Studies of the antimicrobial autophagy pathway and its defects in Inflammatory Bowel Disease
炎症性肠病抗菌自噬途径及其缺陷的研究
- 批准号:
338990 - 财政年份:2015
- 资助金额:
$ 33.75万 - 项目类别:
Fellowship Programs
Xeroderma pigmentosum: a model to study molecular, cellular and clinical consequences of specific defects in the nucleotide excision repair pathway
着色性干皮病:研究核苷酸切除修复途径特定缺陷的分子、细胞和临床后果的模型
- 批准号:
MR/M001210/1 - 财政年份:2014
- 资助金额:
$ 33.75万 - 项目类别:
Fellowship
ACTH receptor pathway defects as the cause of Familial Glucocorticoid Deficiency type 3 (FGD3)
ACTH 受体通路缺陷是导致 3 型家族性糖皮质激素缺乏症 (FGD3) 的原因
- 批准号:
G0801265/1 - 财政年份:2009
- 资助金额:
$ 33.75万 - 项目类别:
Research Grant
To understand the connection between defects in the DNA damage response pathway and tumorigenesis.
了解 DNA 损伤反应途径缺陷与肿瘤发生之间的联系。
- 批准号:
nhmrc : 199633 - 财政年份:2002
- 资助金额:
$ 33.75万 - 项目类别:
Early Career Fellowships
Central Resistance in Diet-Induced-Obesity - Defects and Interaction of the Leptin and Insulin Signaling Pathway
饮食引起的肥胖的中枢抵抗 - 瘦素和胰岛素信号通路的缺陷和相互作用
- 批准号:
5314038 - 财政年份:2001
- 资助金额:
$ 33.75万 - 项目类别:
Emmy Noether International Fellowships














{{item.name}}会员




